At a glance
ClinicalIndex Comparison RecordN/ACompleted· 118 enrolled
Drug / intervention
Pump +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target
In Brief
A clinical study evaluating Pump and CGMS Gold for Type 2 Diabetes. Completed, enrolled 118 participants across 2 sites.
Detailed Summary
This is a prospective, randomized (open label), multi-center and post-market study. The study is to compare effectiveness of sensor-augmented pump (SAP) therapy versus multiple daily injection (MDI) therapy in hospitalized patients with insulin treating type 2 diabetes in China
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedAug 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedAug 13, 2013
Enrollment StartApr 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.9 years ago
Interventions
Pumpdevice
722 Paradigm Real-Time System
CGMS Goldother
Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm